Company Overview & Advantages

Company Overview

Novelwise Pharmaceutical is a biopharmaceutical company dedicated to the discovery and development of a series of histone deacetylase (HDAC) inhibitor programs for oncology and other diseases with high unmet medical needs. Originally the R&D division of NatureWise Pharmaceutical Corporation, Novelwise was established as an independent entity in 2023 to accelerate global drug development.

Global Expansion

Headquartered in Taipei and expanding internationally, the company established a U.S. office in 2024. Novelwise is advancing a pipeline of selective HDAC inhibitors, including a lead program targeting uveal melanoma (UM) with liver metastasis, which has now entered Phase Ib/II clinical trials in the United States. By integrating cutting-edge science, global expertise, and patient-focused innovation, Novelwise is committed to delivering breakthrough medicines that improve survival and quality of life.

Corporate Vision

Novelwise identifies and develops innovative therapies with the potential to fundamentally change the way patients are treated. Our central philosophy is to uncover promising targets and therapeutic approaches that remain underexplored, validate their efficacy through well-designed clinical trials, and advance them to clinical Proof-of-Concept. By focusing on a series of selective and specific HDAC inhibitor programs, along with other epigenetic therapies, Novelwise is committed to delivering transformative medicines that address high unmet needs, improve patient outcomes, and extend human life. Our vision is to be recognized as an international biopharmaceutical company that unites value creation with innovative drug development..